Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Fineline Cube May 18, 2026
Company Deals

Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia

Fineline Cube May 18, 2026
Company Deals

Eli Lilly Commits $50M to UNICEF USA Alliance Targeting Non-Communicable Disease Prevention in Children Across 21 LMICs

Fineline Cube May 15, 2026
Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Policy / Regulatory

China Issues National Guidelines for Home Hospital Bed Services to Address Healthcare Access for Vulnerable Populations

Fineline Cube May 15, 2026
Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Fineline Cube May 18, 2026
Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Fineline Cube May 18, 2026
Company Drug

Simcere Pharmaceutical’s ADC189 NDA Accepted for Influenza Treatment

Fineline Cube Mar 17, 2025

Simcere Pharmaceutical Group Limited (HKG: 2096) and AnDiConBio announced that the New Drug Application (NDA)...

Company

Rona Therapeutics Secures $25M Pre-B Round to Advance siRNA Therapies

Fineline Cube Mar 16, 2025

Shanghai-based Rona Therapeutics announced the successful completion of a $25 million (RMB 180 million) Pre-B...

Company

Tonghua Golden-Horse Pharmaceutical Embraces AI with DeepSeek R1 for Drug Innovation

Fineline Cube Mar 16, 2025

Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. (SHE: 000766) recently held a special meeting to deploy...

Digital

DeepSeek’s Rise in the Pharmaceutical Industry: A New Era of AI-Driven Transformation

Fineline Cube Mar 15, 2025

The emergence of DeepSeek-R1 during the Lunar New Year celebrations marked a pivotal moment in...

Company Deals

Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development

Fineline Cube Mar 15, 2025

Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan...

Company Drug

Roche’s Itovebi Approved in China for PIK3CA-Mutated Breast Cancer

Fineline Cube Mar 14, 2025

Itovebi (inavolisib), a best-in-class PI3Kα inhibitor from Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY), has...

Company Deals

Quantum Hi-Tech and ECNU Establish AI-Driven Drug Manufacturing Lab

Fineline Cube Mar 14, 2025

CRO+CDMO Quantum Hi-Tech (China) Biotechnology Co., Ltd (ChemPartner, SHE: 300149) announced plans to establish an...

Company Deals

BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial

Fineline Cube Mar 14, 2025

China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp...

Company Deals Hospital

Shanghai Fosun Pharmaceutical Transfers Unicorn II Holdings Stake to Warburg Pincus Subsidiary

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced plans to transfer...

Company Deals

Salipro Biotech and Boehringer Ingelheim Collaborate on Drug Development for Membrane Proteins

Fineline Cube Mar 14, 2025

Sweden-based Salipro Biotech AB announced a research and license agreement with German pharmaceutical giant Boehringer...

Company Drug

CSPC Pharmaceutical Group Receives FDA Approval for SYH2051 Clinical Trial

Fineline Cube Mar 14, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced receiving approval from the US Food and...

Company Medical Device

Gaush Meditech’s ANTERION Ophthalmic Detector Receives NMPA Market Approval

Fineline Cube Mar 14, 2025

Suzhou-based Gaush Meditech Ltd (HKG: 2407) announced receiving market approval from the National Medical Products...

Company Drug

Bio-Thera Solutions’ BAT2506 Biosimilar Accepted for Review by China’s NMPA

Fineline Cube Mar 14, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that a market filing for its BAT2506, a...

Company Drug

Otsuka and Lundbeck Win EU Approval for Rxulti in Adolescent Schizophrenia

Fineline Cube Mar 14, 2025

Japan-based Otsuka Pharmaceutical Co., Ltd and its Danish partner Lundbeck A/S (OTCMKTS: HLUBF) jointly announced...

Company Drug

Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment

Fineline Cube Mar 14, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced receiving clinical trial...

Company Drug

Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai

Fineline Cube Mar 14, 2025

China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody...

Company Drug

Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial

Fineline Cube Mar 14, 2025

China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...

Company Drug

Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke

Fineline Cube Mar 14, 2025

China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...

Company Deals

Insilico Medicine Closes USD110 Million Series E Round to Advance AI-Driven Drug Pipeline

Fineline Cube Mar 14, 2025

China’s generative artificial intelligence (AI)-driven biotech Insilico Medicine announced the completion of a USD110 million...

Company Deals

Sanyou Medical Raises RMB214 Million for Stake in SMTP Technology

Fineline Cube Mar 14, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced the completion of a private placement...

Posts pagination

1 … 197 198 199 … 667

Recent updates

  • BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color
  • Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy
  • AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting
  • Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs
  • Allogene Therapeutics Terminates Asian CAR-T Joint Venture with Overland Pharmaceuticals – Strategic Retreat from Allogeneic Cell Therapy Market in Asia
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BMS Partners with Tigerlily Foundation to Address Racial Disparities in Breast Cancer Clinical Trial Access – Pharma Giant Commits to Improving Representation of Young Women of Color

Company Drug

Regeneron’s Fianlimab-Cemiplimab Combination Fails to Meet Primary Endpoint in Phase III Melanoma Trial – LAG-3/PD-1 Dual Therapy Shows No PFS Benefit Over Pembrolizumab Monotherapy

Company Drug

AstraZeneca’s Baxfendy Secures FDA Approval for Uncontrolled Hypertension – First-in-Class Aldosterone Synthase Inhibitor with Selective CYP11B2 Targeting

Company Drug

Harbour BioMed Unveils Preclinical Data for LET003 – AI-Discovered ACVR2A/2B Antibody Shows Best-in-Class Potential in Obesity Combination Therapy with GLP-1 Drugs

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.